Scarica l'app Stockscreener
18.05
3.80%
0.66
Dopo l'orario di chiusura:
18.27
0.22
+1.22%
Precedente Chiudi:
$17.39
Aprire:
$16.79
Volume 24 ore:
1.52M
Relative Volume:
1.57
Capitalizzazione di mercato:
$881.70M
Reddito:
-
Utile/perdita netta:
$-695.98M
Rapporto P/E:
-0.0549
EPS:
-328.6331
Flusso di cassa netto:
$-143.65M
1 W Prestazione:
+33.01%
1M Prestazione:
+13.52%
6M Prestazione:
-50.79%
1 anno Prestazione:
+42.35%
Intervallo 1D:
$16.79
$19.31
Intervallo di 1 settimana:
$13.64
$19.70
Portata 52W:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Nome
Vor Biopharma Inc
Settore
Industria
Telefono
617-655-6580
Indirizzo
500 BOYLSTON STREET, BOSTON
Compare VOR vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
18.05 | 881.70M | 0 | -695.98M | -143.65M | -328.63 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-19 | Iniziato | Wells Fargo | Overweight |
| 2026-01-09 | Iniziato | Citigroup | Buy |
| 2025-12-17 | Iniziato | TD Cowen | Buy |
| 2025-12-09 | Iniziato | JP Morgan | Overweight |
| 2025-11-25 | Ripresa | Wedbush | Neutral |
| 2025-10-15 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | Aggiornamento | Stifel | Hold → Buy |
| 2025-06-30 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | Iniziato | Wedbush | Outperform |
| 2022-04-27 | Iniziato | Goldman | Neutral |
| 2021-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-03 | Iniziato | Robert W. Baird | Outperform |
| 2021-12-02 | Iniziato | Oppenheimer | Outperform |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-03-25 | Iniziato | B. Riley Securities | Buy |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-03-03 | Iniziato | Evercore ISI | Outperform |
| 2021-03-02 | Iniziato | Goldman | Sell |
| 2021-03-02 | Iniziato | Stifel | Buy |
Mostra tutto
Vor Biopharma Inc Borsa (VOR) Ultime notizie
Vor Biopharma (VOR) upgraded to buy: Here's why - MSN
Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold - MarketBeat
Wall Street analysts predict a 107.82% upside in Vor Biopharma (VOR): Here's what you should know - MSN
Jefferies initiates coverage of Vor Biopharma (VOR) with buy recommendation - MSN
Vor Biopharma (VOR) Upgraded to Buy: Here's Why - Yahoo Finance
Wall Street experts anticipate that Vor Biopharma (VOR) could surge by 107.82%: Key Information You Need to Know - Bitget
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know - Yahoo Finance
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Chen Yu and TCG entities hold 10.5% of Vor Biopharma (NASDAQ: VOR) - Stock Titan
TCG Crossover funds in Vor (VOR) disclose 2,836,539 common shares - Stock Titan
Vor Biopharma (VOR) ownership update shows RA Capital at 19.9% - Stock Titan
Vor Bio announces $75M private placement - MSN
Wedbush Maintains 'Neutral' Rating, Raises Price Target for Vor Biopharma (VOR) to $15 | VOR Stock News - GuruFocus
Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price - MarketBeat
Jefferies Financial Group Upgrades Vor Biopharma (NASDAQ:VOR) to Strong-Buy - MarketBeat
Vor Biopharma Inc. (VOR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What's behind the jump in Vor Biopharma stock? - MSN
Jefferies Initiates Coverage on Vor Biopharma (VOR) with a "Buy" Rating | VOR Stock News - GuruFocus
Vor Biopharma, Inc. (VOR) PT Lowered to $48 at Jefferies - StreetInsider
Stifel cuts Vor Biopharma stock price target on financing assumptions - Investing.com
Stifel cuts Vor Biopharma stock price target on financing assumptions By Investing.com - au.investing.com
Vor Biopharma, Inc. (VOR) PT Lowered to $40 at Stifel - StreetInsider
Vor Bio Announces $75 Million Private Placement with TCGX - marketscreener.com
Risk Check: What are Vor Biopharma Incs technical support levels2026 Rallies & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Vor Bio Annual Report 2025: Telitacicept Global Development Strategy, Regulatory Overview, and Summary Risk Factors - Minichart
Jefferies Financial Group Initiates Coverage on Vor Biopharma (NASDAQ:VOR) - MarketBeat
Vor Biopharma Q4 profit tops estimates on warrant fair value gain - TradingView
Vor Biopharma (NASDAQ: VOR) secures $75M to fund autoimmune pipeline - Stock Titan
Vor 10-K: $696.0M Net Loss, Operating Expenses $371.6M; Cash Runway Into Early 2029 - TradingView
VOR: 2025 saw a $696M net loss, major restructuring, and a strategic shift to autoimmune therapies - TradingView
Vor Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Baird Upgrades Vor Biopharma (VOR) - MSN
Jefferies initiates Vor Biopharma stock with buy rating on autoimmune pivot - Investing.com Canada
Jefferies initiates Vor Biopharma stock with buy rating on autoimmune pivot By Investing.com - Investing.com South Africa
Jefferies Starts Vor Biopharma, Inc. (VOR) at Buy - StreetInsider
Vor Biopharma Shares Climb 6.4% Premarket Aft - Moomoo
Vor Biopharma Announces $75 Million Private Placement Financing - TipRanks
What's Behind The Jump In Vor Biopharma Stock? - Benzinga
Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Highe - Benzinga
Vor Biopharma Raises $75 Million in Private Placement With TCGX, Adds Registration Rights - TradingView
Vor Bio announces $75 million private placement with TCGX - marketscreener.com
Vor Bio (Nasdaq: VOR) secures $75M private placement to fund telitacicept - Stock Titan
$75 million gives Vor Bio cash to push two Phase 3 drug trials - Stock Titan
Vor Biopharma Inc. announced that it expects to receive $74.999996 million in funding from TCG Crossover Management, LLC - marketscreener.com
Profit Recap: What are analysts price targets for Vor Biopharma IncQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vor Biopharma Inc Azioni (VOR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):